Lifeward（LFWD）株式概要
医療機器メーカーであるライフワード社は、米国、ヨーロッパ、ドイツ、アジア太平洋地域、そして世界各国において、身体的・神経的疾患を持つ人々のリハビリテーションや日常生活におけるモビリティとウェルネスを可能にする技術の設計、開発、商品化を行なっている。 詳細
LFWD Community Fair Values
Create NarrativeSee what 11 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Lifeward Ltd. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$7.33 |
| 52週高値 | US$10.56 |
| 52週安値 | US$4.14 |
| ベータ | 0.39 |
| 1ヶ月の変化 | 1.10% |
| 3ヶ月変化 | 3.97% |
| 1年変化 | -0.68% |
| 3年間の変化 | -85.69% |
| 5年間の変化 | -93.54% |
| IPOからの変化 | -99.90% |
最新ニュース
ナラティブ更新 • Jun 18
LFWD: Long Term Safety Data Will Support Stock Upside Potential
Analysts have modestly adjusted their price target on Lifeward, keeping fair value steady at $20.00. They fine tuned assumptions around the discount rate, profit margin, and future P/E to reflect updated valuation work, without a clear directional shift in the overall outlook.ナラティブ更新 • Jun 04
LFWD: Higher Expected Revenue And Future P/E Multiple Will Support Upside
Analysts have raised their price target for Lifeward to $10 from $4.50, citing updated assumptions on revenue growth, profit margins, discount rate, and future P/E that support a higher valuation framework. What's in the News On May 15, 2026, Lifeward said it will not be able to file its next 10-Q by the SEC deadline, indicating a delay in its upcoming quarterly report.Recent updates
ナラティブ更新 • Jun 18
LFWD: Long Term Safety Data Will Support Stock Upside Potential
Analysts have modestly adjusted their price target on Lifeward, keeping fair value steady at $20.00. They fine tuned assumptions around the discount rate, profit margin, and future P/E to reflect updated valuation work, without a clear directional shift in the overall outlook.ナラティブ更新 • Jun 04
LFWD: Higher Expected Revenue And Future P/E Multiple Will Support Upside
Analysts have raised their price target for Lifeward to $10 from $4.50, citing updated assumptions on revenue growth, profit margins, discount rate, and future P/E that support a higher valuation framework. What's in the News On May 15, 2026, Lifeward said it will not be able to file its next 10-Q by the SEC deadline, indicating a delay in its upcoming quarterly report.ナラティブ更新 • May 16
LFWD: Lower Discount Rate And Higher P/E Assumptions Support Upside Potential
Analysts have lifted their price target on Lifeward to $10 from $4.50, citing updated assumptions around discount rates, long term profit margins, and future P/E levels that feed into their fair value framework. Analyst Commentary Analysts revising their fair value frameworks for Lifeward point to changes in discount rates, long term margin assumptions, and targeted P/E levels as key drivers behind the new US$10 price target.
ナラティブ更新 • Apr 30
LFWD: Higher Fair Value Assumptions Will Shape Future P E Repricing
Analysts have raised their price target on Lifeward to $10 from $4.50, citing updated assumptions related to fair value, discount rate, revenue growth, profit margin and future P/E estimates. Analyst Commentary Bearish analysts describe the move to a US$10 price target as a recalibration rather than a clear vote of confidence, pointing out that the new target still reflects uncertainty around how Lifeward can deliver on the assumptions used in updated fair value work.
ナラティブ更新 • Apr 15
LFWD: Higher Risk Reward View Will Support Future Upside Potential
Analysts have raised their price target on Lifeward to $10 from $4.50, citing updated assumptions for revenue growth, profit margins, and a lower future P/E multiple that together change their view of the company’s balance of risk and reward. Analyst Commentary Bullish analysts are framing the new US$10 price target as a reassessment of Lifeward’s potential risk and reward, rather than just a reaction to short term news.ナラティブ更新 • Mar 31
LFWD: Higher Fair Value Assumptions Will Support Future Cash Flow
Analysts have lifted the price target for Lifeward to $10 from $4.50, citing updated views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. Analyst Commentary Analysts lifting the Lifeward price target to $10 from $4.50 are updating their view of what they see as fair value, based on refreshed assumptions for revenue growth, profitability, discount rates, and future P/E levels.ナラティブ更新 • Mar 17
LFWD: Reverse Split And Convertible Notes Will Support Future Upside
Analysts have raised their price target on Lifeward from $10.00 to about $120.00, citing updated views on revenue growth, profit margins, and a lower assumed future P/E multiple. What's in the News Lifeward plans dedicated clinic days with Shirley Ryan AbilityLab in Chicago starting in the second quarter of 2026, focused on evaluation and access to the FDA cleared ReWalk Personal Exoskeleton for people with spinal cord injury (Key Developments).ナラティブ更新 • Mar 03
LFWD: Reverse Split And New Financing Will Support Future Cash Flow
Analysts have lifted their price target for Lifeward to $87.00, supported by updated assumptions around fair value, discount rate, revenue growth, profit margin, and a lower future P/E multiple. What's in the News Lifeward plans a 1 for 12 reverse split of its ordinary shares, effective at the open of trading on February 24, 2026.ナラティブ更新 • Feb 17
LFWD: Convertible Notes And Share Actions Will Drive Future P E Repricing
Analysts have modestly adjusted their price target on Lifeward, citing updated assumptions around discount rate, revenue growth, profit margin, and future P/E that slightly refine their view of the company’s risk and earnings power in dollar terms. What's in the News Lifeward plans a Special and Extraordinary Shareholders Meeting on March 12, 2026 at its Hudson, Massachusetts offices to address corporate matters previously approved in principle at earlier meetings (company event filing).ナラティブ更新 • Feb 03
LFWD: New Convertible Funding And Reverse Split Will Support Future Upside
Narrative Update on Lifeward Analysts have slightly reduced their price target for Lifeward, citing small adjustments to the discount rate and future P/E assumptions, along with modest changes to expected revenue growth and profit margins. What's in the News Lifeward completed a private placement on November 14, 2025, issuing secured convertible promissory notes with an aggregate principal of $3,000,000, carrying 15% annual interest and convertible into ordinary shares at $0.45 per share, with participation from Oramed Ltd and maturity on May 14, 2026 (Key Developments).ナラティブ更新 • Jan 20
LFWD: Future P/E Repricing Will Rely On Successful Convertible Note Execution
Analysts have raised their price target for Lifeward to reflect higher modelled revenue growth of about 53% and a very large future P/E multiple, even as they factor in a lower profit margin and a slightly higher discount rate. What's in the News Lifeward entered into a private placement agreement to issue Senior Secured Convertible Notes with a principal amount of $20,000,000 and accompanying warrants, with the notes initially convertible at $0.45 per share and accruing 8.0% annual interest that may rise to 15.0% in the event of default (Key Developments).ナラティブ更新 • Jan 06
LFWD: Reverse Split And New Funding Will Set Up Future Upside
Analysts have reduced their fair value estimate for Lifeward from US$13.00 to US$10.00. They attribute this change to more conservative assumptions on revenue growth, profit margins and the P/E multiple they apply to the company.ナラティブ更新 • Dec 17
LFWD: Improved Capital Structure Will Support Future Cash Flow Potential
Analysts have nudged their price target for Lifeward slightly higher to reflect marginally lower perceived risk and modest improvements in long term profitability and valuation assumptions, even as their underlying fair value estimate remains anchored around $5.17 per share. What's in the News Lifeward completed a $3 million private placement via secured convertible promissory notes bearing 15% interest, convertible at $0.45 per share and maturing May 14, 2026, with participation from Oramed Ltd.ナラティブ更新 • Dec 03
LFWD: Improved Medicare Reimbursement Trends Will Support Future Cash Flow
Narrative Update on Lifeward The analyst price target for Lifeward has been revised upward to approximately 5.17 dollars per share from 5.17 dollars previously. This reflects analysts' expectations for faster revenue growth, improved profit margins, and a lower future price to earnings multiple.ナラティブ更新 • Nov 19
LFWD: Rising Medicare Approvals And New Funding Will Support Revenue Outlook
Analysts have significantly lowered their price target for Lifeward from $8.00 to approximately $5.17. They cite more conservative revenue growth projections and a notable reduction in expected profit margins.分析記事 • Sep 25
Even With A 27% Surge, Cautious Investors Are Not Rewarding Lifeward Ltd.'s (NASDAQ:LFWD) Performance Completely
Despite an already strong run, Lifeward Ltd. ( NASDAQ:LFWD ) shares have been powering on, with a gain of 27% in the...ナラティブ更新 • Aug 16
FDA Clearance And Expanded Payer Channels Will Drive Advanced Mobility
The consensus price target for Lifeward has been revised down to $8.00, primarily reflecting a sharp decrease in its future P/E multiple, while profitability remains stable. What's in the News Lifeward reset full-year 2025 earnings guidance under new management, targeting revenue of $24–$26 million.分析記事 • Jun 19
Many Still Looking Away From Lifeward Ltd. (NASDAQ:LFWD)
With a price-to-sales (or "P/S") ratio of 0.5x Lifeward Ltd. ( NASDAQ:LFWD ) may be sending very bullish signals at the...新しいナラティブ • May 11
AlterG NEO And ReWalk 70 Will Shape Future Market Opportunities
Established lump sum payments and expanded into U.S. workers' compensation, creating stable revenue streams and improving net margins through efficient claim processing.分析記事 • Feb 05
Market Cool On Lifeward Ltd.'s (NASDAQ:LFWD) Revenues Pushing Shares 50% Lower
Lifeward Ltd. ( NASDAQ:LFWD ) shareholders won't be pleased to see that the share price has had a very rough month...分析記事 • Oct 30
Not Many Are Piling Into Lifeward Ltd. (NASDAQ:LFWD) Stock Yet As It Plummets 25%
Unfortunately for some shareholders, the Lifeward Ltd. ( NASDAQ:LFWD ) share price has dived 25% in the last thirty...分析記事 • Oct 15
Here's Why Lifeward (NASDAQ:LFWD) Must Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...分析記事 • Aug 01
ReWalk Robotics Ltd. (NASDAQ:LFWD) Soars 26% But It's A Story Of Risk Vs Reward
ReWalk Robotics Ltd. ( NASDAQ:LFWD ) shareholders are no doubt pleased to see that the share price has bounced 26% in...分析記事 • May 30
Is ReWalk Robotics (NASDAQ:LFWD) In A Good Position To Deliver On Growth Plans?
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...株主還元
| LFWD | US Medical Equipment | US 市場 | |
|---|---|---|---|
| 7D | -7.2% | -1.2% | -2.1% |
| 1Y | -0.7% | -12.8% | 18.8% |
業界別リターン: LFWD過去 1 年間で-12.8 % の収益を上げたUS Medical Equipment業界を上回りました。
リターン対市場: LFWDは、過去 1 年間で18.8 % のリターンを上げたUS市場を下回りました。
価格変動
| LFWD volatility | |
|---|---|
| LFWD Average Weekly Movement | 7.5% |
| Medical Equipment Industry Average Movement | 8.4% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
安定した株価: LFWD 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: LFWDの 週次ボラティリティ ( 7% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 2001 | 81 | William Grant | golifeward.com |
医療機器メーカーであるライフワード社は、米国、欧州、ドイツ、アジア太平洋地域、および国際的に、身体的・神経的疾患を持つ人々のリハビリテーションや日常生活におけるモビリティとウェルネスを可能にする技術の設計、開発、商品化を行っている。同社は、脊髄損傷者向けの個人用外骨格およびリハビリ用外骨格デバイスReWalk、脳卒中による下肢障害者のリハビリ用ソフト外スーツReStore Exo-Suit、身体・神経リハビリおよびアスレチック・トレーニング用AlterG Anti-Gravity System、MyoCycleデバイス、脳卒中後遺症者の自宅や地域社会で使用する個人用ソフト外スーツReBootを提供している。同社は医療機関や個人に直接製品を販売するほか、第三者の販売代理店を通じて製品を販売している。同社は以前はReWalk Robotics Ltd.として知られていたが、2024年9月に社名をLifeward Ltd.に変更した。Lifeward Ltd.は2001年に法人化され、イスラエルのYokneam Illitに本社を置いている。
Lifeward Ltd. 基礎のまとめ
| LFWD 基礎統計学 | |
|---|---|
| 時価総額 | US$20.59m |
| 収益（TTM） | -US$30.83m |
| 売上高(TTM) | US$21.82m |
1.0x
P/Sレシオ-0.7x
PER（株価収益率LFWD は割高か？
公正価値と評価分析を参照収益と収入
| LFWD 損益計算書（TTM） | |
|---|---|
| 収益 | US$21.82m |
| 売上原価 | US$13.98m |
| 売上総利益 | US$7.85m |
| その他の費用 | US$38.68m |
| 収益 | -US$30.83m |
直近の収益報告
Jun 30, 2026
次回決算日
該当なし
| 一株当たり利益（EPS） | -10.89 |
| グロス・マージン | 35.95% |
| 純利益率 | -141.28% |
| 有利子負債／自己資本比率 | 36.3% |
LFWD の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/08/20 18:17 |
| 終値 | 2026/08/20 00:00 |
| 収益 | 2026/06/30 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Lifeward Ltd. 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。7
| アナリスト | 機関 |
|---|---|
| Matthew Taylor | Barclays |
| William Plovanic | Canaccord Genuity |
| Swayampakula Ramakanth | H.C. Wainwright & Co. |